{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T23:13:48Z","timestamp":1792970028807,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.hlc.2024.07.013","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T07:03:55Z","timestamp":1731999835000},"page":"34-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Cross-Sectional Study of Capillary Blood Ketone Concentrations in Heart Failure Based on Sodium-Glucose Co-Transporter-2 Inhibitor Use and Heart Failure Type"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-3166","authenticated-orcid":false,"given":"Jia Yong","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke Andrew","family":"Ephraums","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Mark","family":"Inglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen Thi Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh Michael","family":"Umapathysivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Jane","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4011-6561","authenticated-orcid":false,"given":"Josephine Helen","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Mary","family":"Burdeniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine Gerardo","family":"De Pasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-7716","authenticated-orcid":false,"given":"Tilenka Rosemary Jenni","family":"Thynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2024.07.013_bib1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2024.07.013_bib2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2024.07.013_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2024.07.013_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2024.07.013_bib5","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2024.07.013_bib6","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2024.07.013_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5694\/mja2.51656","article-title":"Consensus statement on the current pharmacological prevention and management of heart failure","volume":"217","author":"Sindone","year":"2022","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2024.07.013_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5694\/mja2.50899","article-title":"Sodium\u2013glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis","volume":"214","author":"Meyer","year":"2021","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2024.07.013_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s44161-023-00259-1","article-title":"Ketones and the cardiovascular system","volume":"2","author":"Lopaschuk","year":"2023","journal-title":"Nat CardioVasc Res"},{"key":"10.1016\/j.hlc.2024.07.013_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2024.07.013_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.hlc.2024.07.013_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2024.07.013_bib13","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.transproceed.2021.08.017","article-title":"Sodium-glucose Cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis after orthotopic heart transplant in a prediabetic patient: a case report","volume":"53","author":"Cha","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.hlc.2024.07.013_bib14","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s13300-018-0417-1","article-title":"Prediabetes directly deteriorates into diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome triggered by acute pancreatitis: a case report illustrating a \u201cchicken and egg\u201d paradigm in ketosis-prone diabetes","volume":"9","author":"Song","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.hlc.2024.07.013_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc23-1163","article-title":"Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium\u2013glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction","volume":"47","author":"Umapathysivam","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.hlc.2024.07.013_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5694\/mja2.52067","article-title":"Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes","volume":"219","author":"Raven","year":"2023","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2024.07.013_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12933-021-01410-7","article-title":"Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure","volume":"20","author":"Pietschner","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.hlc.2024.07.013_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cardfail.2022.09.009","article-title":"Longitudinal changes in circulating ketone body levels in patients with acute heart failure: a post hoc analysis of the EMPA-response-AHF trial","volume":"29","author":"Voorrips","year":"2023","journal-title":"J Card Fail"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950624017700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950624017700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T22:07:10Z","timestamp":1740607630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950624017700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1443950624017700"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2024.07.013","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Cross-Sectional Study of Capillary Blood Ketone Concentrations in Heart Failure Based on Sodium-Glucose Co-Transporter-2 Inhibitor Use and Heart Failure Type","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2024.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}